Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Peter Dragovich - Staff Scientist, Discovery Chemistry

Peter Dragovich

Staff Scientist, Discovery Chemistry

Staff Scientist
"I'm interested in identifying new molecules which can be utilized as novel therapeutic agents to treat serious diseases with unmet needs."
11
Years at Genentech
48
Publications

I’ve worked in the pharmaceutical industry for more than 20 years at both large and small organizations. Much of my early career was spent discovering novel antiviral agents for the treatment of HIV, HCV, and respiratory illnesses. Since coming to Genentech in 2010, I have contributed to multiple discovery-stage projects that span a variety of different therapeutic areas. My Genentech research includes studies in immunology, cancer metabolism, epigenetics, and (most-recently) antibody-drug conjugates. I greatly enjoy the diversity of the science conducted at Genentech and have learned many new things since joining the organization.

Featured Publication

Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).

J. Med. Chem. 2014, 57, 770

Giannetti AM, Zheng X, Skelton NJ, Wang W, Bravo BJ, Bair KW, Baumeister T, Cheng E, Crocker L, Feng Y, Gunzner-Toste J, Ho YC, Hua R, Liederer BM, Liu Y, Ma X, O0Brien T, Oeh J, Sampath D, Shen Y, Wang C, Wang L, Wu H, Xiao Y, Yuen PW, Zak M, Zhao G, Zhao Q, Dragovich PS.